HIGHLIGHTED ARTICLES FROM ANNALS OF SURGICAL ONCOLOGY
Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma
February 15, 2024
Citation: Zhu, XD., Huang, C., Shen, YH. et al. Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma. Ann Surg Oncol 30, 2782–2790 (2023). https://doi.org/10.1245/s10434-022-12530-z
Synopsis: The authors reviewed a cohort of 101 patients with advanced/unresectable hepatocellular carcinoma (HCC) who received first-line treatment with a tyrosine kinase inhibitors (TKI) plus anti-PD-1 antibodies and report the rate of patients who subsequently underwent R0 resection, clinical features associated with clinical downstaging, and long-term survival outcomes in patients who underwent R0 resection.
Circulating Tumor DNA Is Unreliable to Detect Somatic Gene Alterations in Gastrointestinal Peritoneal Carcinomatosis
February 15, 2024
Citation: Sullivan, B.G., Lo, A., Yu, J. et al. Circulating Tumor DNA Is Unreliable to Detect Somatic Gene Alterations in Gastrointestinal Peritoneal Carcinomatosis. Ann Surg Oncol 30, 278–284 (2023). https://doi.org/10.1245/s10434-022-12399-y
Synopsis: ctDNA is now routinely used to guide treatment decisions in patients with gastrointestinal (GI) cancers. The authors found that ctDNA levels are significantly low and plasma ctDNA-NGS is unreliable to detect tumor somatic gene alterations in GI peritoneal carcinomatosis.
Listen to the ASO's new podcast, Speaking of SurgOnc®
Speaking of SurgOnc® is a podcast brought to you by the Annals of Surgical Oncology (ASO) and the Society of Surgical Oncology (SSO).
The series is hosted by ASO Deputy Editor Dr. Frederick L. (Rick) Greene, who will expand upon ideas from articles published in the Annals. Once a month, Dr. Greene will interview authors and leading experts in surgical oncology.
Listen to the podcast here.
ASO is the journal of choice of surgical oncologists and cancer multidisciplinary teams worldwide regarding surgical oncology research and education, and benefits surgeons, oncologists, hematologists, radiologists, general practitioners, pathologists, researchers, academicians, and other clinical professionals interested in all aspects of the surgical treatment of cancer. ASO strives to improve the practice environment in which high-quality surgical oncology care is delivered, to enhance the quality of life and survival of the surgical patient with cancer.